Business Wire

FUJIREBIO

Share
Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Fujirebio Europe and Self-screen B.V. today announced an expansion of their commercial collaboration with the distribution of the PreCursor-M AnoGYN methylation-specific molecular assay from Self-screen B.V. The test is intended for the detection of promoter hypermethylation of the genes ASCL1 and ZNF582 and is used to test the methylations status of anal specimens for research use only (RUO). It complements Fujirebio's HPV-associated molecular test portfolio.

“The Human Papilloma Virus (HPV) test panel of Fujirebio Europe continues to grow with effective and accurate testing solutions, and we are pleased to add this new RUO methylation-based assay to our molecular testing toolbox,” says Christiaan De Wilde, CEO at Fujirebio Europe “With its unmatched accuracy and reliability, this innovative PreCursor-M AnoGYN assay represents a significant advancement for research studies in the field of anal cancer prevention. We wanted our customers to have access to this valuable research tool as soon as possible, ultimately catalyzing advancements in elimination of HPV-related diseases.”

We are very happy with the continued partnership with Fujirebio in the distribution of Self-screen’s HPV tests and methylation tests, says Michelle Meijer, Chief Commercial Officer at Self-screen B.V. The PreCursor-M AnoGYN extends our offering of HPV products into the field of anal cancer. Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions. The growing medical need for better and more supportive diagnostics tools for HPV related cancers such as anal cancer drove us to the development of the PreCursor-M AnoGYN RUO assay which is now available through Fujirebio.”

About host cell DNA methylation and anal cancer

Incidence of anal cancer is increasing worldwide. The majority of anal cancers are squamous cell carcinoma (SCC) and are, like cervical cancer, mainly caused by a persistent high-risk HPV infection and preceded by high-grade squamous intraepithelial lesion (HSIL). In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate. Host cell DNA methylation is an epigenetic hallmark of HPV-induced carcinogenesis. The PreCursor-M AnoGYN assay is a robust and reliable tool to further investigate host cell DNA methylation in anal carcinogenesis and study its potential as a valuable biomarker for the detection of anal (pre-)cancer.1-4

Please contact Fujirebio for further information about the local availability of the test.

About Self-screen B.V.

Self-screen B.V. is a company highly experienced in translational HPV related research, assay development and commercialization of In Vitro Diagnostics (IVD).

Our dedication is towards the development and clinical application of molecular assays for the early detection of anogenital and head & neck (pre)cancers, to the benefit of patients and health care programs around the world.

Our main focus is on cervical (pre)cancer screening and prevention. Self-screen markets two clinically validated CE-IVD assays. The HPV-Risk-Assay and the PreCursor-M+ Methylation Test, for screening and triage respectively, to support full molecular cervical screening and to assist the clinician in management of women with high-grade CIN. Recently PreCursor-M AnoGYN RUO is added. For more information, visit www.self-screen.nl.

About Fujirebio

Fujirebio is a global leader in the field of high-quality IVD testing. We have more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products.

Fujirebio has a long-lasting tradition for developing high-quality routine and truly novel biomarkers. Our IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions covering a variety of disease states.

Our global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network. For more information, visit www.fujirebio.com.

References:

  1. van der Zee R.P. , et al. Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer. Clin. Infect. Dis., 68 (7); 1110-1117, 2019
  2. van der Zee R.P. , et al. Cancer risk stratification of anal intraepithelial neoplasia in human immunodeficiency virus-positive men by validated methylation markers associated with progression to cancer. Clin. Infect. Dis., 72 (12); 2154-2163, 2021
  3. van der Zee R.P. , et al. DNA methylation markers have universal prognostic value for anal cancer risk in HIV-negative and HIV-positive individuals. Mol. Oncol., 15 (11); 3024-3036, 2021, 2021
  4. Rozemeijer K, et al. Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer. Tumour Virus Res. 30;17:200275, 2023

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240304661911/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xsolla Launches Loyalty as a Service for Game Developers to Build Stronger Connections With Players11.3.2025 18:00:00 CET | Press release

Empowering Developers With Tools To Boost Retention, Increase Revenue, And Foster Deeper Engagement On Their Terms Xsolla, a leading global video game commerce company, announces the launch of an innovative, customizable loyalty as a service solution designed to help developers seamlessly integrate rewards into their games’ purchase flows. This solution empowers developers to increase LTV and convert more non-paying players by enabling them to earn and redeem points, boosting engagement, retention, and recurring revenue while requiring minimal setup. The developers’ loyalty programs can be set up across direct-to-consumer stores, web shops, and Xsolla Pay Station for a seamless checkout experience for players. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250311773400/en/ Graphic: Xsolla Unlike programs offered by third-party platforms, Xsolla’s solution ensures developers retain complete control over user data and relation

Japan’s WAFUU.COM Launches Cryptocurrency Payments: 16 Supported Assets, 83 Wallets, 22 Exchanges11.3.2025 15:10:00 CET | Press release

Seamless Global Transactions: WAFUU.COM Embraces Crypto 1. Overview QRESTIA Inc. (Headquarters: Shibuya, Tokyo; President & CEO: Hidemasa Fukada) is pleased to announce that its cross-border e-commerce site, WAFUU.COM, has started accepting cryptocurrency payments. Customers worldwide can now purchase Japanese products more easily and securely using 16 different cryptocurrencies, supported by 83 wallets and 22 exchanges. 2. About WAFUU.COM WAFUU.COM (https://wafuu.com/) is a cross-border e-commerce site offering a diverse range of Japanese products, including traditional crafts, confectionery, cosmetics, supplements, food items, anime and gaming merchandise, and gadgets. With support for 21 languages, multiple currency options, and seamless cryptocurrency payments, WAFUU.COM ensures a reliable and speedy shopping experience for customers in over 70 countries. By leveraging cutting-edge technology, the site is committed to breaking down barriers of distance, language, and currency to pr

Allegro DVT Acquires Vicuesoft to Build a Worldwide Leader in Video Codecs Compliance and Analysis Solutions11.3.2025 15:00:00 CET | Press release

Allegro DVT, the worldwide leader in video codec compliance test suites and semiconductor video IPs, announces that it has completed the acquisition of Vicuesoft, the leading provider of video quality and bitstream analysis solutions. Vicuesoft, a Cyprus based company, is at the leading edge of video codec technologies. It develops and commercializes a series of video codec analysis and compliance solutions that includes the renowned VQ Analyzer bitstream analysis software used by video experts worldwide. VQ Analyzer carries out deep inspection of video bitstreams by providing valuable insights into the encoding process to help with video quality tuning as well as into the essential steps of the decoding process. Vicuesoft’s portfolio also includes VQ DVK and VQ Probe, respectively video decoder compliance solution and video codec quality measurement tool. The combination of Allegro DVT and Vicuesoft video codec compliance teams and product portfolios creates an undisputed leader with

Bynder Expands Board Members With Industry Veteran11.3.2025 14:45:00 CET | Press release

Bynder, a global leader in AI-powered enterprise DAM has appointed industry veteran Dametra Johnson-Marletti to its board of directors to further accelerate its growth. Dametra is a seasoned executive and board member, and has spent the last 24 years at Microsoft where she is currently Corporate Vice President for Gaming Consumer Sales. Her experience in sales, go-to-market, consumer content and executive leadership will be extremely valuable to Bynder as it continues to scale. Bynder has experienced unprecedented growth in the last two years, with more than 650 customers adopting the company’s AI solutions, and the acceleration of strategic DAM deployments among enterprise customers. The company has also been recognized as a leader across all three top analyst DAM reports including the Gartner DAM Magic Quadrant, Forrester Wave, and IDC Marketscape. Bynder has also secured its leadership position in the G2 Enterprise Grid Report for Digital Asset Management for two consecutive years.

ZAPI GROUP to Feature Fleet Management Innovations at LogiMAT 202511.3.2025 14:00:00 CET | Press release

Global leader in electric drive solutions enhances its portfolio with new solutions from BlueBotics and UBIQUICOM ZAPI GROUP, a global leader in electrification, is unveiling its latest solutions for the material handling and logistics sectors at LogiMAT 2025. The electrification innovator is featuring its new autonomous navigation technology “ANT Locator” from BlueBotics and recent acquisition UBIQUICOM, reinforcing its leadership in fleet management with next-generation automated navigation, asset tracking, and leading-edge “Real-Time” locating and advanced safety systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250311742968/en/ ZAPI GROUP adds new fleet management solutions from BlueBotics and UBIQUICOM to its portfolio. (Graphic: Business Wire) “For decades, ZAPI GROUP has been at the forefront of material handling electrification, delivering engineered solutions that enhance equipment efficiency and operator safe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye